Astrazeneca (AZN) ended the recent trading session at $75.57, demonstrating a +1.79% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.49% gain on the day. On the ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as a perioperative treatment for patients with resectable ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

In trading on Tuesday, shares of AstraZeneca plc (Symbol: AZN) crossed below their 200 day moving average of $74.95, changing hands as low as $74.87 per share. AstraZeneca plc shares are currently ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...